drugset / Trial / NCT02191163

Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency

NCT02191163 ↗

Phase 2 Completed 71 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Study to determine the efficacy and safety of Antistax® film coated tablets in improving microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)

Timeline

Start
2002-04
Primary completion
2002-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Antistax Unknown 360 mg Oral